GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships

Health and Healthcare

Published: July 3, 2012 7:35 am

Last Updated: April 27, 2020 10:08 pm

GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This one has partnerships with Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc. (NASDAQ: GILD) and has five candidates under various stage trials.

Celgene is a 16% owner, Healthcare Ventures is a 14% owner, Morgenthaler is a 14% owner, and Lilly Ventures has more than a 6% stake and that is a $200 million fund tied originally to Eli Lilly & Co. (NYSE: LLY).

Book runners are listed as Wells Fargo Securities and Piper Jaffray, with JMP Securities as a co-manager.

The company description: “We are a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines, which predominately stimulate antibody production. We have four Tarmogen product candidates in five ongoing clinical trials.”

GlobeImmunue’s lead cancer product candidate, GI-4000, is being evaluated in combination with gemcitabine in a fully-enrolled, placebo-controlled Phase 2b trial in resected pancreas cancer. Its lead infectious disease product candidate, GI-5005, has completed a randomized, active-control Phase 2b trial in chronic hepatitis C virus, or HCV, infection.

GlobeImmune has two strategic collaborations, one with Celgene Corporation for all oncology product candidates and one with Gilead Sciences, Inc. for chronic hepatitis B virus, or HBV, infection.

Of course this company is pre-revenue so it has nothing but losses to show to date.

FULL SEC FILING

JON C. OGG

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.